April 06, 2026

Skin Fluorescent Imaging Shows High Sensitivity, Specificity for Discriminating Melanoma Lesions

Skin fluorescent imaging demonstrated high sensitivity and specificity for the discrimination of low- and high-risk lesions, showing an alternative, noninvasive approach to melanoma biopsies, accordin...

The ASCO Post

April 06, 2026

Tanning Bed Exposure and Melanoma Risks

Research has elucidated how radiation from tanning beds increases the mutation burden across a broad area of melanocytes, thereby significantly raising the risk of developing melanoma. Findings publis...

The ASCO Post

April 06, 2026

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation

In a systematic review and meta-analysis published in JAMA Dermatology, Laiouar-Pedari et al evaluated the real-world diagnostic performance of artificial intelligence (AI)–assisted dermoscopy for mel...

The ASCO Post

March 30, 2026

Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies

Explore the latest advances in metastatic melanoma treatment from leading experts at Mass General Hospital.

JADPRO

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post

September 19, 2023

Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab

In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues investigated the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodru...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

August 21, 2023

Ipilimumab Plus Nivolumab May Improve Outcomes in Patients With Refractory Metastatic Melanoma, Study Suggests

Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent s...

The ASCO Post

January 05, 2024

Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer

Researchers investigated the potential of a rare subset of T cells to predict which patients with advanced skin cancer may be responsive to immunotherapy.

The ASCO Post

February 19, 2024

FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma

On February 16, the FDA granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, for previously treated adult patients with unresectable or metastatic mel...

The ASCO Post